Ten months ago, bird flu made its presence known in viral infections in cows. At least 68 people in North America have fallen ill from the pathogen as well. Now, when the debate about bird flu’s potential to become a severe health risk is on, a group of scientists at the University of Pittsburgh and NIH have developed a broadly neutralizing antibody that can prevent severe H5N1 infections in monkeys. The antibody targets the stable region of the virus, which reduces the risk of the virus escaping from the immune system. This antibody is stable and can remain effective for weeks, preventing outbreaks. The research serves as a step towards universal flu vaccine development.
The bird flu virus H5N1 has caused just one death as of January 2025; however, the ability of the virus to jump into mammals has been well recorded, with sea lions infected in South America and mink in Europe, apart from cattles in North America. Genetic analysis of two human samples have shown that the virus is now adapting and is getting better at causing disease in mammals.
Developing vaccines against influenza virus is quite challenging due to their ability to mutate over the years. This makes it necessary to reformulate a new vaccine every year against the most dominant strains. However, antibody-based prophylactic measure can target the stalk region of the infectious protein hemagglutinin which is preserved across different influenza isolates over the years. This allows for a broad spectrum action, helping us proceed towards an universal flu vaccine. In an analogy presented by co-corresponding author Simon Barratt-Boyes, Ph.D., professor of infectious diseases and microbiology at Pitt’s School of Public Health and immunology at Pitt’s School of Medicine, he states that the virus is more like a tree— different species have different leaves, but the tree trunks look the same. Similarly, the stalk region of the bird flu virus closely resembles the same structure as seasonal flu, allowing stalk-targeting proteins to provide universal protection.
In the latest study, monkeys pre-treated with a moderate dose of broadly neutralizing MEDI8852 antibody were immunized against the virus, leading to a less severe disease and no death. The antibody’s efficacy in preevnting the disease was quite convincing. In addition, the researchers also established the minimum serum concentration required for protection, a measurement needed for identifying the protective threshold of a plausible universal flu vaccine. The protection lasted for 8-12 weeks and it suggests that if provided early , it can protect first responders and others caring for patients at the begining of an H5N1 outbreak.
Copyright @smorescience. All rights reserved. Do not copy, cite, publish, or distribute this content without permission.
